Superseded public profile

FDA-approved↗Metabolic↗

Superseded · version 3: Lixisenatide↗

Related names recorded in this version: Soliqua 100/33↗

A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

We added a preserved FDA-hosted product label to support the product-specific label account. Prior profile versions retain their original citations. 2

What this version reported

The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗

Sources for this version

  1. 1
    SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    ADLYXIN, revised November 2024: U.S. prescribing information ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026